ArcticZymes Technologies Confirms New Board of Directors Following Annual General Meeting Approval
Tromsø, Norway – June 27, 2024 – ArcticZymes Technologies ASA (OSE: AZT) is pleased to announce the successful approval of its new Board of Directors at the recent Annual General Meeting.
This marks a significant milestone for the company, as we welcome a diverse and accomplished group of leaders poised to guide ArcticZymes towards a future of continued innovation and sustainable growth. Each new board member brings unique expertise and a wealth of experience that will be invaluable in advancing our strategic initiatives and enhancing long-term stakeholder value.
Dr. Frank Mathias has been appointed as the new Chairman of the Board. Dr. Mathias is the CEO at Oxford Biomedica, a leading pure-play CDMO within the cell and gene therapy industry. Dr. Mathias was previously the CEO of Rentschler Biopharma SE, which he successfully developed into a leading global, full-service CDMO. Before Rentschler, Dr. Mathias served as CEO of Medigene AG, a publicly listed immuno-oncology company. During his 30-year career, Dr. Mathias has held senior roles at leading global pharmaceutical companies, including Amgen Deutschland GmbH, Servier Deutschland GmbH, and Hoechst AG. In 2019, he was awarded the “EY Entrepreneur of the Year” title in Germany. Dr. Mathias is a pharmacist by training and completed his Doctorate in Pharmacy at Paris VI University.
“I am honoured to join ArcticZymes at such a pivotal time,” said Dr. Frank Mathias. “The innovative enzyme solutions developed by ArcticZymes have made significant contributions to advancements in biomanufacturing, enhancing efficiency and quality across the industry. I look forward to contributing to the company’s continued success and collaborative growth.”
Mrs. Sharon Brownlow joins the board bringing extensive experience in the life sciences sector. Sharon Brownlow has a background in Biotech and extensive experience in the cell and gene therapy industry, Mrs. Brownlow is renowned for blending her scientific roots with entrepreneurial drive. Her proven track record includes senior commercial roles in Catapult and Cobra Biologics, where she effectively drove strategic business momentum and long-term revenue growth.
Mr. Petter Dragesund has also been appointed as a board member. Mr. Dragesund is a former Senior Partner at Pareto Securities and has boasts nearly three decades of experience in investment banking. Serving in various capacities at Pareto from 1992 to 2021, including Head of the Corporate Finance department from 2001 to 2014, he brings invaluable financial acumen to the Board. Since 2021, Mr. Dragesund has been an independent investor, further broadening his insights into market dynamics.
“We are excited to welcome such a diverse and accomplished group of leaders to our Board of Directors,” said Michael Akoh, CEO of ArcticZymes. “Their combined expertise and strategic insights will be crucial as we advance our innovative enzyme solutions and expand our impact in biomanufacturing, molecular research, and diagnostics. We are confident that these appointments will significantly contribute to our mission of driving scientific advancement and delivering exceptional value to our stakeholders.”
For more information, please contact:
ArcticZymes Technologies ASA
CEO, MIchael B. Akoh, Tel: +46 (0) 70 262 37 15
CFO, Børge Sørvoll, Tel: +47 95 29 01 87
ir@arcticzymes.com
